Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BSofiva Genomics 〉Non-Invasive Prenatal Screening, NIPS

Non-Invasive Prenatal Screening, NIPS

Non-Invasive Prenatal Screening, NIPS

By using whole genome NGS and chromosome database from Taiwan and Illumina, Non-invasive prenatal screening, NIPS, could examine chromosomal diseases, such as Trisomy21, Trisomy18, Trisomy13 and 3 microdeletion syndromes.

Request for Collaboration
Overview
The non-invasive prenatal screening, NIPS, which SOFIVA Genomics cooperate with illumina®, collects 10 c.c. blood from pregnant women, and extracts the cell-free fetal DNA (cffDNA) of fetus. With high throughput and analysis technique of whole genome next-generation sequencing, we have combined the chromosome database in Taiwan with global database for overall analysis. This screening technique could examine whether the fetus suffers from chromosomal diseases, such as Down Syndrome (T21), Edwards Syndrome (T18) and Patau Syndrome (T13).

The outstanding genetic screening technique and strength of SOFIVA Genomics win the favor of illumina®, the leading company of gene sequencing in the world, and the cooperation has started since 2015 to provide pregnant women with excellent international screening services.
 
SOFIVA Genomics collaborates with illumina®, introduces the patented technique, SAFeR™, which is accumulated and tested worldwide and has the global database of 500,000 clinical cases. Moreover, NIPS is guaranteed by ISO/IEC 17025 certification. By combining the conscientious clinical data and the innovative thinking, we build a precise prenatal chromosomal screening with high accuracy.
 
Features
1. INTERNATIONAL COOPERATION
Cooperate with illumina® and introduce the patented technique, SAFeR™, with its clinical database, which was accumulated and tested worldwide and applied in many medical centers.
 
2. WHOLE GENOME SEQUENCING
Make a perfect clinical use of NGS to analyze chromosome aneuploidy and 3 microdeletion syndrome with the database of 500,000 clinical cases.
 
3. 8 WORKING DAYS
Certified by ISO/IEC 17025 that the whole process will all be accomplished in Taiwan with high quality and standard, and the screening result can be reported in 8 working days only.
 
4. NON-INVASIVE
Become a trend in the world, which is recommended by society of OB/GYN. The non-invasive procedure won't lead to miscarriage and infection, and which is safe without risk.
 
5. 10 WEEKS SCREENING
The earlier you detect, the more relieved you will be. NIPS can be applied for pregnant women at 10 weeks of gestation. The detection rate is up to 99.5%

6. CLINICAL SUPPORT
With the complete and detailed reports, physicians examine thoroughly and provide the service of heredity consultation.
 
Application
Indications of SOFIVA NIPS
 
American Congress of Obstetricians and Gynecologists (ACOG) proved the effectiveness of non-invasive prenatal screening in December, 2012. After SOFIVA Genomics and illumina® co-construct a complete database, we could recommend it to more pregnant women.
 
To those pregnant women:
≧ 34-year-old
worry about the risk of invasive test
find abnormal ultrasound screening
have doubt of chromosomal aneuploidies
have baby born with chromosomal aneuploidies
have high risk in serum screening of Down Syndrome
People who like this also like
  • PhytoHealth EnerCharge ®CapsulePhytoHealth EnerCharge ®Capsule
  • HEPAVASE MA-96 (TMB)HEPAVASE MA-96 (TMB)
  • Anatomic Precision PSI HTOAnatomic Precision PSI HTO
  • Migus-Nutrients for DiabetesMigus-Nutrients for Diabetes
  • Cut FlowerCut Flower
  • Bendamustine Lyo inj.Bendamustine Lyo inj.
  • Inpheno Tablets 100 mg(Sapropterin Dihydrochloride)Inpheno Tablets 100 mg(Sapropterin Dihydrochloride)
  • A (H1N1) Influenza VaccineA (H1N1) Influenza Vaccine
  • SURASE B-96 (TMB)SURASE B-96 (TMB)
  • AmpholipadAmpholipad